CALC Archived Articles

CalciMedica Inc. (NASDAQ:CALC): Leveraging Novel CRAC Channel Inhibition to Tackle Acute and Chronic Inflammatory Conditions


CalciMedica, Inc. (NASDAQ:CALC): Advancing Novel CRAC Channel Inhibition Therapies for Acute and Chronic Inflammatory Conditions


CalciMedica, Inc. (NASDAQ:CALC): A Promising CRAC Channel Inhibitor Targeting Acute and Chronic Inflammatory Diseases